Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J. González Larriba JL, et al. Among authors: puente j. Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S11-7. doi: 10.1007/s10555-012-9354-z. Cancer Metastasis Rev. 2012. PMID: 22674353 Review.
SEOM clinical guidelines for the treatment of renal cell carcinoma.
Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I; Spanish Society for Medical Oncology. Bellmunt J, et al. Among authors: puente j. Clin Transl Oncol. 2014 Dec;16(12):1043-50. doi: 10.1007/s12094-014-1219-1. Epub 2014 Oct 2. Clin Transl Oncol. 2014. PMID: 25274276 Free PMC article.
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study.
Munárriz J, Reynés G, Sánchez-Lorenzo L, Esteban E, Basterretxea L, de Avila-Lizárraga L, Climent MA, Juan-Fita MJ, Escoín C, Puente J, Cassinello J, Vázquez S, Chirivella I. Munárriz J, et al. Among authors: puente j. Cancer Chemother Pharmacol. 2019 Oct;84(4):781-789. doi: 10.1007/s00280-019-03913-3. Epub 2019 Jul 31. Cancer Chemother Pharmacol. 2019. PMID: 31367791
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
Pal SK, Puente J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Ciuleanu T, Lee JL, Sunela K, O'Hara K, Binder TA, Peng L, Smith AD, Rha SY. Pal SK, et al. Among authors: puente j. Eur Urol. 2022 Sep;82(3):283-292. doi: 10.1016/j.eururo.2021.12.024. Epub 2022 Feb 21. Eur Urol. 2022. PMID: 35210132 Free article. Clinical Trial.
408 results